265 related articles for article (PubMed ID: 15496217)
1. The safety and tolerability of donepezil in patients with Alzheimer's disease.
Jackson S; Ham RJ; Wilkinson D
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):1-8. PubMed ID: 15496217
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease.
Farlow M; Veloso F; Moline M; Yardley J; Brand-Schieber E; Bibbiani F; Zou H; Hsu T; Satlin A
BMC Neurol; 2011 May; 11():57. PubMed ID: 21612646
[TBL] [Abstract][Full Text] [Related]
5. Clinical profile of donepezil in the treatment of Alzheimer's disease.
Doody RS
Gerontology; 1999; 45 Suppl 1():23-32. PubMed ID: 9876215
[TBL] [Abstract][Full Text] [Related]
6. Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.
Rogers SL
Dement Geriatr Cogn Disord; 1998; 9 Suppl 3():29-42. PubMed ID: 9853200
[TBL] [Abstract][Full Text] [Related]
7. Donepezil: tolerability and safety in Alzheimer's disease.
Pratt RD; Perdomo CA; Surick IW; Ieni JR
Int J Clin Pract; 2002 Nov; 56(9):710-7. PubMed ID: 12469988
[TBL] [Abstract][Full Text] [Related]
8. Donepezil-related toxic hepatitis.
Dierckx RI; Vandewoude MF
Acta Clin Belg; 2008; 63(5):339-42. PubMed ID: 19186568
[TBL] [Abstract][Full Text] [Related]
9. A large, community-based, open-label trial of donepezil in the treatment of Alzheimer's disease.
Relkin NR; Reichman WE; Orazem J; McRae T
Dement Geriatr Cogn Disord; 2003; 16(1):15-24. PubMed ID: 12714795
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study.
Farlow MR; Salloway S; Tariot PN; Yardley J; Moline ML; Wang Q; Brand-Schieber E; Zou H; Hsu T; Satlin A
Clin Ther; 2010 Jul; 32(7):1234-51. PubMed ID: 20678673
[TBL] [Abstract][Full Text] [Related]
11. The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Thompson S; Lanctôt KL; Herrmann N
Expert Opin Drug Saf; 2004 Sep; 3(5):425-40. PubMed ID: 15335298
[TBL] [Abstract][Full Text] [Related]
12. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
13. The pharmacology of donepezil: a new treatment of Alzheimer's disease.
Wilkinson DG
Expert Opin Pharmacother; 1999 Nov; 1(1):121-35. PubMed ID: 11249555
[TBL] [Abstract][Full Text] [Related]
14. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Cooke JR; Loredo JS; Liu L; Marler M; Corey-Bloom J; Fiorentino L; Harrison T; Ancoli-Israel S
Drugs Aging; 2006; 23(6):503-11. PubMed ID: 16872233
[TBL] [Abstract][Full Text] [Related]
15. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Lockhart IA; Mitchell SA; Kelly S
Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
18. Donepezil use in Alzheimer disease.
Barner EL; Gray SL
Ann Pharmacother; 1998 Jan; 32(1):70-7. PubMed ID: 9475825
[TBL] [Abstract][Full Text] [Related]
19. Donepezil: an update.
Seltzer B
Expert Opin Pharmacother; 2007 May; 8(7):1011-23. PubMed ID: 17472546
[TBL] [Abstract][Full Text] [Related]
20. Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Touchon J; Bergman H; Bullock R; Rapatz G; Nagel J; Lane R
Curr Med Res Opin; 2006 Jan; 22(1):49-59. PubMed ID: 16393430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
